Inglese

Eligibility Criteria

5 moduli  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, and affection status of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
    3. Subject ID, sample ID, and sample use of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
    4. Subject ID, case or control, age, gender, and race of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
    5. Sample ID, body site where sample was collected of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
Inclusion and exclusion criteria
Descrizione

Inclusion and exclusion criteria

*Inclusion criteria*
Descrizione

Inclusion criteria

Tipo di dati

boolean

Cases: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) With angioedema, defined by swelling of the lips, tongue, pharynx, or face while taking an ACE inhibitor.
Descrizione

Cases: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) With angioedema, defined by swelling of the lips, tongue, pharynx, or face while taking an ACE inhibitor.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C1706256
UMLS CUI [1,3]
C0001779
UMLS CUI [2,1]
C1512693
UMLS CUI [2,2]
C1706256
UMLS CUI [2,3]
C0085756
UMLS CUI [2,4]
C0221786
UMLS CUI [3,1]
C1512693
UMLS CUI [3,2]
C1706256
UMLS CUI [3,3]
C0002994
UMLS CUI [3,4]
C0003015
Controls: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) Taken and ACE inhibitor for at least 6 months and never experienced angioedema; 4) May include subjects who experienced cough.
Descrizione

Controls: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) Taken and ACE inhibitor for at least 6 months and never experienced angioedema; 4) May include subjects who experienced cough.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0009932
UMLS CUI [1,3]
C0001779
UMLS CUI [2,1]
C1512693
UMLS CUI [2,2]
C0009932
UMLS CUI [2,3]
C0085756
UMLS CUI [2,4]
C0221786
UMLS CUI [3,1]
C1512693
UMLS CUI [3,2]
C0009932
UMLS CUI [3,3]
C0003015
UMLS CUI [3,4]
C4082120
UMLS CUI [3,5]
C2003901
UMLS CUI [3,6]
C0002994
UMLS CUI [4,1]
C1512693
UMLS CUI [4,2]
C0009932
UMLS CUI [4,3]
C0010200
*Exclusion criteria for all subjects*
Descrizione

Exclusion criteria for all subjects

Tipo di dati

boolean

1) History of angioedema while not taking an ACE inhibitor; 2) Angioedema only involves the bowel; 3) Decreased C1 inhibitor or complement concentrations; 4) Mental conditions which render the subject unable to understand the nature, scope, and possible consequences of the study.
Descrizione

1) History of angioedema while not taking an ACE inhibitor; 2) Angioedema only involves the bowel; 3) Decreased C1 inhibitor or complement concentrations; 4) Mental conditions which render the subject unable to understand the nature, scope, and possible consequences of the study.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0002994
UMLS CUI [1,3]
C0003015
UMLS CUI [2,1]
C0680251
UMLS CUI [2,2]
C3888796
UMLS CUI [3,1]
C0680251
UMLS CUI [3,2]
C0205216
UMLS CUI [3,3]
C0540301
UMLS CUI [3,4]
C0009498
UMLS CUI [4,1]
C0680251
UMLS CUI [4,2]
C3841804
Ritorna all'inizio della pagina

Similar models

Eligibility Criteria

5 moduli
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, and affection status of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
    3. Subject ID, sample ID, and sample use of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
    4. Subject ID, case or control, age, gender, and race of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
    5. Sample ID, body site where sample was collected of participants with or without angioedema and involved in the "A Genome-Wide Association Analysis in Angiotensin-Converting enzyme (ACE) Inhibitor-Associated Angioedema and ACE Inhibitor-Exposed Controls; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Center for Genomic Medicine" project.
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Inclusion and exclusion criteria
Inclusion criteria
Item
*Inclusion criteria*
boolean
Cases: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) With angioedema, defined by swelling of the lips, tongue, pharynx, or face while taking an ACE inhibitor.
Item
Cases: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) With angioedema, defined by swelling of the lips, tongue, pharynx, or face while taking an ACE inhibitor.
boolean
C1512693 (UMLS CUI [1,1])
C1706256 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,3])
C1512693 (UMLS CUI [2,1])
C1706256 (UMLS CUI [2,2])
C0085756 (UMLS CUI [2,3])
C0221786 (UMLS CUI [2,4])
C1512693 (UMLS CUI [3,1])
C1706256 (UMLS CUI [3,2])
C0002994 (UMLS CUI [3,3])
C0003015 (UMLS CUI [3,4])
Controls: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) Taken and ACE inhibitor for at least 6 months and never experienced angioedema; 4) May include subjects who experienced cough.
Item
Controls: 1) Men or women age 18 or older; 2) African- or Caucasian-Americans; 3) Taken and ACE inhibitor for at least 6 months and never experienced angioedema; 4) May include subjects who experienced cough.
boolean
C1512693 (UMLS CUI [1,1])
C0009932 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,3])
C1512693 (UMLS CUI [2,1])
C0009932 (UMLS CUI [2,2])
C0085756 (UMLS CUI [2,3])
C0221786 (UMLS CUI [2,4])
C1512693 (UMLS CUI [3,1])
C0009932 (UMLS CUI [3,2])
C0003015 (UMLS CUI [3,3])
C4082120 (UMLS CUI [3,4])
C2003901 (UMLS CUI [3,5])
C0002994 (UMLS CUI [3,6])
C1512693 (UMLS CUI [4,1])
C0009932 (UMLS CUI [4,2])
C0010200 (UMLS CUI [4,3])
Exclusion criteria for all subjects
Item
*Exclusion criteria for all subjects*
boolean
1) History of angioedema while not taking an ACE inhibitor; 2) Angioedema only involves the bowel; 3) Decreased C1 inhibitor or complement concentrations; 4) Mental conditions which render the subject unable to understand the nature, scope, and possible consequences of the study.
Item
1) History of angioedema while not taking an ACE inhibitor; 2) Angioedema only involves the bowel; 3) Decreased C1 inhibitor or complement concentrations; 4) Mental conditions which render the subject unable to understand the nature, scope, and possible consequences of the study.
boolean
C0680251 (UMLS CUI [1,1])
C0002994 (UMLS CUI [1,2])
C0003015 (UMLS CUI [1,3])
C0680251 (UMLS CUI [2,1])
C3888796 (UMLS CUI [2,2])
C0680251 (UMLS CUI [3,1])
C0205216 (UMLS CUI [3,2])
C0540301 (UMLS CUI [3,3])
C0009498 (UMLS CUI [3,4])
C0680251 (UMLS CUI [4,1])
C3841804 (UMLS CUI [4,2])
Ritorna all'inizio della pagina